Osteonecrosis of the jaw
ehabnajjar95
Created on January 13, 2021
Bisphosphonate Related Osteonecrosis of the Jaw first semenar in the senior year
Over 30 million people build interactive content in Genially.
Check out what others have designed:
BLENDED PEDAGOGUE
Presentation
WORLD WILDLIFE DAY
Presentation
FOOD AND NUTRITION
Presentation
2021 TRENDING COLORS
Presentation
HISTORY OF THE CIRCUS
Presentation
LETTERING PRESENTATION
Presentation
SPRING HAS SPRUNG!
Presentation
Transcript
Of The Jaw "MRONJ"
Osteonecrosis
medication Related
NECROSIS
BONE
DEATH
Just as the name indicate :
OSTEO
Osteonecrosis of the jaw, commonly called ONJ occurs when the jaw bone is exposed and begins to starve from a lack of blood. The bone starts to weaken and die which usually but not always causes pain.
*The term "osteonecrosis of the jaw" was introduced by Marx in 2003 and subsequently by Ruggiero et al in 2004 as a Non-healing exposed areas of jawbone that were associated with the use of intravenous bisphosphonate therapy “BRONJ”. *In 2009, denosumab was approved by the Food and Drug Administration of the United States (FDA) and the European Medicines Agency (EMA) for the treatment and prevention of bone metastases. *In 2014, the American Association of Oral and Maxillofacial Surgeons (AAOMS) changed the term “Bisphosphonate-Related Osteonecrosis of the Jaws” (BRONJ) to “Medication-Related Osteonecrosis of the Jaws” (MRONJ)
ONJ
MRONJ (medication related)
ARONJ (antiresorptive related)
BRONJ(bisphosphonate related osteonecrosis (of the jaw
8. MEDICATION RELATED OSTEONECROSIS OF THE JAW ( MON, MRONJ)
7. ONJ can be developed spontaneously
6. Anti-angiogenic agents
5. Steroid use
4. Radiation therapy
3 Exogenous estrogens
2. Infections
such as heavy metals; for example Lead and cadmium
1. TOXIC AGENTS
What are the causes of ONJ ?
4) medical oncologists who are prescribing these drugs
3) hospital-based dentists treating oncology patients.
2) dental specialists (mostly OMF surgeons and pathologists)
1) general dentists
has been a major concern for:
particularly in those individuals on high dose parenteral antiresorptive agents
ONJ
Prolia
(Bisphosphonate or Denosumab)
( DENTAL EXTRACTION, PERIO surgery)
MINOR ORAL SURGERY
ANTIRESORPTIVE DRUGS INTAKE
RISK FACTORS For BRONJ :
2) Osteogenesis imperfecta in adults
1) Osteogenesis imperfecta in children
Non FDA approved indications include:
6) malignancies with metastasis to bone
5) Paget disease
4) Hypercalcemia of malignancy
3) Glucocorticoid induced osteoporosis
2) Osteoporosis in men
1) Treatment of osteoporosis in postmenopausal women
FDA-approved indications for bisphosphonates :include
when do we have to anticipate that the patient is taking or took bisphosphonate?
3. Diabetes
4. Smoking
2. Antiangiogenic agents intake
1. Concomitant use of steroids
Other RISK FACTORS FOR MRONJ:
Kidney cancer
Thyroid cancer
Multiple myeloma
Lymphoma
Lung cancer
Prostate cancer
Breast cancer
Virtually any type of cancer can spread to the bones, but the cancers most likely to cause bone metastasis include:
Physiologic bone remodeling
One of the underlying factors is the suppression of natural remodeling process due to the inhibition of osteoclasts.
Despite the possibly linking theories, the pathogenesis of BRONJ has not been entirely understood.
Remodeling is vital for bone healing and the suppression by bisphosphonates diminishes the healing capacity of the bone.
Pathogenesis Of BRONJ
Bisphosphonates have antiangiogenic effects.
Compromised angiogenesis would most likely be involved in post-intervention healing. "VEGF": vascular endothelial growth factor
Antiangiogenic theory of BRONJ
This molecule is a monoclonal antibody to receptor activator RANKL. RANKL binds to its receptor RANK on preosteoclasts as well as osteoclasts which is essential for the formation, function and survival of osteoclasts. Denosumab blocks the binding between RANKL and RANK thus inhibit the function, survival and formation of Osteoclast.
Mechanism Of Action Of Denosumab
Bisphosphonate differ from one another in the substitution of their active side chain.
Bisphosphonate are synthetic analogue of pyrophosphate
Classification Of Bisphosphonates
WHY?
Its is Preferentially deposited in bones with high turnover rate.
Most common sites are nonhealing dentoalveolar sites, traumatized palatal & mandibular tori and exposed portions of the mylohyoid ridge.
It results from greater reliance on osteoclast related remodeling due to occlusion and denture wearing pressure and tension forces.
And almost always began in alveolar bone due to it’s greater bone turnover rate.
BPs induced ON of jaw occurs more frequently in the mandible than maxilla.
Location
Females are more affected than males due to postmenopausal osteoporosis and breast cancer ( high incidence of metastasis to bone )
The relative risk for patients taking oral bisphosphonates for osteoporosis and the development of ONJ is unknown at this time and is estimated to be very low (1:10,000–100,000 patient years on drug therapy).
prevalence
It is clear that the benefit with respect to fracture risk reduction is far greater than the risk of ONJ in osteoporosis patients, and in oncology patients the benefit of antiresorptive therapy in lowering the risk of skeletal related events outweighed the risk of ONJ by a factor of 17
The patients most at risk of developing ONJ are those on monthly IV bisphosphonates or high-dose, subcutaneously administered denosumab (120 mg/month). The reported prevalence in the oncology patient population is between 1 and 16% of patients on high-dose therapy.
3)No history of radiation therapy to the jaws.
2)Exposed bone in the maxillofacial region that has persisted for more than 8 weeks
1)Current or previous treatment with a bisphosphonate
Patients may be considered to have MRONJ if they have all of the following criteria:
The American Society for Bone and Mineral Research define MRONJ as follows
Pain, teeth mobility, mucosal swelling, erythema and ulcerationIntra or Extra oral Fistula Altered sensation in the affected area
Signs and Symptoms
Stage 3: exposed bone with infection and extension radiographically to the inferior border of the mandible or sinus floor in the maxilla or presence of an extra oral fistula or pathologic fracture
Stage 2: exposed bone with evidence of infection with or without purulent discharge
Stage 1: exposed bone with no infection and otherwise asymptomatic
Three stages of ONJ have been proposed and this classification is currently in use.
Imaging is of value in diagnosing ONJ. This is particularly the case in individuals on antiresorptive therapy with ONJ-like symptoms but without obvious bone exposure. As periapical and periodontal disease is an important risk factor for ONJ. identifying early dental disease with imaging and proceeding with dental preventive measures may decrease the risk of ONJ and minimize the need for dental extractions.
Role of Imaging in Diagnosis
Increased trabecular density
It has been proposed that serum C-terminal telopeptide of type-1 collagen (CTX), a break down product of type-1 collagen during bone resorption, can be followed in the patient's serum as a risk indicator for development of ONJ.
What is CTX Blood Test ?
Patient with full or partial dentures should be examined for areas of mucosal trauma
Optimal periodontal health should be achieved
Non restorable teeth and those with poor prognosis should be extracted.
3) Avoiding future extractions
2) Optimizing dental and oral health
1) Patient education
IF IT POSSIBLE THE INITATION OF IV BP THERAPY SHOULD BE DELAYED UNTIL THE DENTAL HEALTH IS OPTIMISED
PREVENTION:
4) providing primary closure over bony wounds wherever possible
3) minimizing sharp bony edges
2) Careful surgical technique
1) prophylactic antibiotic both topical and systemic
If minor surgery is needed should include;
First of all any surgical therapy should be minimized, especially if there is alternative such as endodontic therapy.
Dental Management
It is the simplest and fastest type of wound closure
PRIMARY INTENTION WOUND HEALING :
- Lower the risk of infection
- Minimal tissue loss
- Minimal Scarring
They are at much reduced risk, but there is reported cases and the duration is very important since most reported cases occur after 3 years of exposure.While if there is concomitant steroid use less than 3 years would be enough.
drug holiday FOR THESE PATIENTS DISCONTINUATION OF BP THERAPY BEFORE 3 MONTHS OF SURGERY MAY REDUCE THE RISK
Patients on oral BP
Non restorable teeth that require extraction may be treated by the removal of the crown and endo treatment for the remaining roots.
Procedures that involve direct osseous injury should be avoided.
1-16% of them are at risk.
. Discontinuing the IV medication Provide no short term benefit since the effect of the drug may remain for extended period of time.
Patients On Iv BP
Other routine restorative, hygiene, orthodontic and endodontic dentistry can be conducted as usual.
Surgery should be avoided if possible ( since it is difficult to obtain a surgical margin with viable bleeding because the entire jawbone is under the effect of BP ) Areas of necrotic bone that are source for soft tissue irritation should be removed or recontoured without exposing adjacent bone. Loose segments of bony sequestrum should be removed without exposing the uninvolved bone.
Patient diagnosed to have BRONJ General Principles In Management
Stage 1
Stage Specific Treatment
Oral antimicrobial rinses. No surgical treatment is indicated unless the area of exposed bone are irritating surrounding soft tissues. The patient should be examined every 3 month.
Stage 1
Stage 2
Stage 1
Stage Specific Treatment
Oral antimicrobial rinses. AB ( mostly is sensitive to pencilline, metronidazole, clindamycine and erythromycin). In refractory patient the might need IV antibiotics.
Stage 2
Stage 3
Stage 2
Stage 1
Stage Specific Treatment
The most challenging, usually these cases are refractory to antibiotics At this stage the surgical intervention is indicated + IV antibiotics
Stage 3
two months after dental extraction
painful exposed bone
intravenous zoledronic acid monthly for three years
relapse of the breast cancer with bony metastasis
radiation
chemotherapy
modified radical mastec-tomy
breast cancer
A 42-year-old woman
Case Report
The dentist found yellow-white discoloration of exposed bone, surrounding a soft tissue inflammation.
A radiological study showed bone destruction of the left body of the mandible
therefore, curettage, conservative otoplasty and saline irri- gation was done
Initially, conservative removal of exposed bone with primary closure was performed and systemic antibiotic given Notwithstanding, she developed a non-healing socket surrounded by mucosal inflammation
of her underlying disease in February 2007.
died
lost to follow up
finally she was
at the last visit she still had non-healed socket with mild soft tissue inflammation
underwent saline irrigation multiple times with minimal recovering of affected area
The patient followed up with the dentist
The best way to manage this serious complication is to prevent it from happening
JUST AS ANY DISEAS IN THE WORLD
THANK YOU
referances
Saad F, Brown JE, Van PC, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carriere P, Dansey R Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23:1341-1347. Peters E, Lovas GL, Wysocki GP. Lingual mandibular sequestration and ulceration. Oral Surg Oral Med Oral Pathol. 1993;75:739–43.1.Lee JWY, Bance ML. Physiology of Osseointegration. Otolaryngol Clin North Am. 2019 Apr;52(2):231-242. 2.Basurto-Acevedo L, Saucedo-García R, Vázquez-Martínez A, Cruz-García M, Valle-Hernández MM, Rosales-Cruz E, Sánchez-Arenas R. Relationship between bone remodeling and metabolism in the elderly. Rev Med Inst Mex Seguro Soc. 2018;56(Suppl 1):S6-S11. [PubMed]Aghaloo TL, Felsenfeld AL, Tetradis S Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg. 2010;68:959-963.1. Etminan M, Aminzadeh K, Matthew IR, Brophy JM. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study. J Rheumatol. 2008;35:691–5.2. Tennis P, Rothman KJ, Bohn RL, Tan H, Zavras A, Laskarides C, Calingaert B, Anthony MS. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf. 2012;21:810–17.3. Ulmner M, Jarnbring F, Torring O. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. J Oral Maxillofac Surg. 2014;72:76–82.4. Etminan M, Aminzadeh K, Matthew IR, Brophy JM. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study. J Rheumatol. 2008;35:691–5.
referances
Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, Visvikis A, Nikolakopoulou A, Acholos V, Karapanagiotidis G, Batziou E, Skarlos DV. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology. 2009;76:209–11. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:433–41. 1. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumor patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan Ann Oncol 2009;20:137–45. 2. Bedogni A, Saia G, Ragazzo M, Bettini G, Capelli P, D'Alessandro E, Nocini PF, Lo RL, Lo ML, Blandamura S. Bisphosphonate-associated osteonecrosis can hide jaw metastases. Bone. 2007;41:942–5. Osteonecrosis of the Jaw: An Update for Dentists, Archie Morrison, DDS, MS, FRCD(C); Aliya Khan, MD, FRCP(C), FACP, FACE; Sotirios Tetradis, DDS, PhD; Edmund Peters, DDS, MSc, FRCD(C) , November 27, 2015 Marx RE, Cillo JE, Jr., Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397-2410. J Med Assoc Thai Vol. 90 No. 11 2007